LISCURE BIOSCIENCES CO. LTD.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC) 2024-03-29 21:00
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease 2023-02-20 22:00
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA 2022-12-08 22:00
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022 2022-10-28 21:00
LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology 2022-02-03 22:00
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases 2022-01-06 22:00
LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH 2021-09-30 21:00
LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic 2021-08-02 11:11
LISCure Biosciences Successfully Raises $21 million in Series B Funding 2021-02-26 22:00
LISCure Biosciences Has Completed Seed Funding of USD 5 Million for Bacteria-mediated Immunotherapy R&D Enhancement 2019-07-25 21:00
1